论文部分内容阅读
目的:通过检测凋亡抑制蛋白Livin在非小细胞肺癌患者围手术期血清中的含量,分析其围手术期变化趋势,探讨Livin在非小细胞肺癌诊断、分级、预后判断的临床意义。方法:采用酶联免疫吸附法(ELISA)对40例非小细胞肺癌患者术前、术后血清中Livin的表达水平及20例正常健康人血清Livin水平进行检测。结果:非小细胞肺癌患者血清Livin水平明显高于健康对照组;术前(中位数526.49 ng/L,四分位间距357.93～825.57 ng/L)、术后(中位数286.49 ng/L,四分位间距157.93～515.57 ng/L),两组间存在统计学差异(P<0.05);血清Livin平均水平与非小细胞肺癌临床病理学的关系:Ⅰ、Ⅱ期(中位数326.49 ng/L,四分位间距201.54～623.19 ng/L)与Ⅲ期(中位数586.31 ng/L,四分位间距411.79～965.34 ng/L)之间存在统计学差异(P<0.05);肿瘤淋巴结转移11例(中位数562.03 ng/L,四分位间距382.64～982.61 ng/L)与无淋巴结转移29例(中位数344.59 ng/L,四分位间距167.27～646.20 ng/L)之间存在明显差异(P<0.05);组织学高、中、低分化三组间无明显差异(P>0.05)。结论:Livin作为一种新的凋亡抑制蛋白,对非小细胞肺癌诊断、分期具有一定的临床价值。
Objective: To investigate the perioperative changes of Livin in patients with non-small cell lung cancer (NSCLC) and to investigate the clinical significance of Livin in the diagnosis, classification and prognosis of non-small cell lung cancer. Methods: The expression of Livin in preoperative and postoperative serum of 40 patients with NSCLC and the serum Livin level in 20 healthy controls were detected by enzyme-linked immunosorbent assay (ELISA). Results: Serum Livin levels in non-small cell lung cancer patients were significantly higher than those in healthy controls. Preoperative (median 526.49 ng / L, interquartile range 357.93-825.57 ng / L), postoperative (median 286.49 ng / L , Interquartile range from 157.93 to 515.57 ng / L). There was a significant difference between the two groups (P <0.05). The relationship between the serum level of Livin and the clinicopathological features of non-small cell lung cancer: stage Ⅰ and Ⅱ (median 326.49 There was a significant difference (P <0.05) between the interquartile range (201.54 ~ 623.19 ng / L) and stage Ⅲ (median 586.31 ng / L, interquartile range 411.79-965.34 ng / L) There were 11 cases with tumor lymph node metastasis (median 562.03 ng / L, interquartile range 382.64 ~ 982.61 ng / L) and no lymph node metastasis (median 344.59 ng / L, interquartile range 167.27 ~ 646.20 ng / L ) (P <0.05). There was no significant difference between the three groups (P> 0.05). Conclusion: Livin, as a novel inhibitor of apoptosis protein, has certain clinical value for the diagnosis and staging of non-small cell lung cancer.